ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

QTTB vs BCYC // GROSS PROFIT MARGIN

Q32 Bio Inc. (NASDAQ) VS. Bicycle Therapeutics plc (NASDAQ) • 15-METRIC TALLY: QTTB 5 — BCYC 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QTTB VS. BCYC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC QTTB BCYC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -35.00% +120.00 QTTB /roic <GO>
EV/EBITDA & P/E Valuation 12.8x — — TIE /valuation <GO>
Free Cash Flow Yield -12.70% — — TIE /fcf-yield <GO>
Operating Margin 31.50% -60.00% +91.50 QTTB /operating-margins <GO>
Net Profit Margin 55.50% -60.00% +115.50 QTTB /net-margins <GO>
Revenue Growth (YoY) — 105.80% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.99 0.20 +5.79 QTTB /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 QTTB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.6 53.5 -5.90 BCYC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 8.3x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $264.1M $267.4M -$3.3M BCYC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR QTTB REV BCYC REV QTTB GROSS % BCYC GROSS % QTTB FCF BCYC FCF
FY 2025 $53.7M $72.6M — — -$33.5M -$252.0M
FY 2024 $0 $35.3M — — -$67.8M -$166.0M
FY 2023 $1.2M $27.0M — — -$18.7M -$60.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QTTB // BETA —
BCYC // BETA —